Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for DAYBUE ...

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his ‘Powerplay’ stock ...

Acadia Pharmaceuticals Inc., a company is advancing breakthroughs in neuroscience to elevate life, announced that the company has submitted a Marketing Authorization Application (MAA) to the European ...

The context: The biopharmaceutical company saw its share price tumble on Wednesday after its US partner Acadia Pharmaceuticals applied for approval to market its Rett syndrome treatment, trofinetide, ...

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett ...

Acadia Pharma's trofinetide has hit its efficacy targets in a phase 3 trial involving girls with the devastating neurological disorder Rett syndrome, although safety has dampened enthusiasm a little.

Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome ...

This announcement revealed that Neuren's partner, Acadia Pharmaceuticals, has submitted a marketing authorization application to the European Medicines Agency for its trofinetide treatment.